Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Sequencing Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

NCT02125357 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT02125357
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02125357 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Sequencing Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
British Columbia Cancer Agency
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2014
Completion date
February 4, 2020
Enrollment
202 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer